We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Immune Cells Hampered Fighting Soft Tissue and Bone Sarcomas

By LabMedica International staff writers
Posted on 06 Jul 2020
Print article
Image: Aggregates of immune cells known as tertiary lymphoid structures (TLSs), seen here within a tumor of the soft tissues known as a rhabdomyosarcoma, are major players in the immune system’s fight against cancer (Photo courtesy of Johns Hopkins Kimmel Cancer Center).
Image: Aggregates of immune cells known as tertiary lymphoid structures (TLSs), seen here within a tumor of the soft tissues known as a rhabdomyosarcoma, are major players in the immune system’s fight against cancer (Photo courtesy of Johns Hopkins Kimmel Cancer Center).
Immunotherapies such as checkpoint inhibitors that enhance the body's natural ability to fight cancer have been only minimally successful in treating sarcomas which are rare cancers that grow in the soft tissues and bones.

There are many subtypes of sarcoma, which are classified based on the specific tissue and type of cell from which the tumor originates. Sarcomas are primary connective tissue tumors, meaning that they arise in connective tissues. This is in contrast to secondary (or "metastatic") connective tissue tumors, which occur when a cancer from elsewhere in the body (such as the lungs, breast tissue or prostate) spreads to the connective tissue.

Oncologists at the Johns Hopkins Kimmel Cancer Center (Baltimore, MD, USA) and their numerous colleagues interrogated the tumor microenvironment (TME) of two contrasting soft-tissue sarcomas (STS), rhabdomyosarcomas and undifferentiated pleomorphic sarcomas (UPS), with differing genetic underpinnings and responses to immune checkpoint inhibition to understand the mechanisms that lead to response. The team used fresh and formalin-fixed, paraffin-embedded tissue from patients diagnosed with UPS and rhabdomyosarcomas, and dissected the TME by using immunohistochemistry (IHC), flow cytometry, and comparative transcriptomic studies.

The investigators discovered that both tumor types were ripe with tumor-associated macrophages (TAMs). Heavily involved in promoting tumor initiation and growth, TAMs hamper the proper immune reaction against tumors. Additionally, both sarcomas had similar amounts of CD8+ T lymphocytes (CD 8+ T cells are also known as "killer T cells"), immune system cells that protect the body from infection and are believed to be among the front-line soldiers in the fight against cancers. They also discovered that where the CD8+ T cells congregated and how their antitumor functions were impeded by TAMs differed in the two sarcomas.

In UPS, the group found that the tumors themselves were filled with TAMs and CD8+ T cells. With constant stimulation by tumor antigens, CD8+ cells produce large amounts of PD-1, a protein that eventually exhausts the T cell population. When this happens, the authors suggest, and TAMs control the environment, normal T cell activity against the cancer is suppressed. In rhabdomyosarcomas, they found CD8+ T cells only within tiny aggregates of immune cells called tertiary lymphoid structures (TLSs). TLSs are known to play a major role in initiating antitumor immune responses, helping the immune system recognize cancer cells as targets.

Nicolas Llosa, MD, an assistant professor of oncology and senior author of the study said, “The basis of successful immunotherapy lies in the ability of the immune system to recognize cancer as foreign and attack, and is dependent on genetics, host and environmental factors, and makeup of the tumor microenvironment. We need to understand the immune niche that sustains these tumors and how it supports tolerance, so we can determine what drug targets could be used to help mount a better response.”

The authors concluded that their work in soft tissue sarcomas revealed an immunosuppressive TME dominated by myeloid cells, which may be overcome with activation of T cells that traffic into the tumor. In rhabdomyosarcomas, targeting T cells found within TLS may be crucial to achieve antitumor response. The study was published on June 16, 2020 in the journal Clinical Cancer Research.

Related Links:
Johns Hopkins Kimmel Cancer Center

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.